Leuprorelin and Triptorelin in the treatment of Prostate Cancer: Medication adherence, Persistence and Economic Evaluation in Five Years of Analysis : Table 2

Table 2: Sum of days of treatment, as median and range, RDD weighted, PDD weighted and Adherence weighted, as mean ± Standard Deviation, for Leuprorelin and Triptorelin from 2007 to 2012.

Drug	Leuprorelin 3.75 – 11.25
Years	2007		2008		2009		2010		2011		2012
Sum of days of treatment
Median	360		360		360		360		360		360
Range	90	360	30	365	56	365	84	365	84	365	60	365
WRDD
Mean ± SD	0.12	0.03	0.12	0.03	0.12	0.02	0.12	0.02	0.12	0.02	0.12	0.02
WPDD
Mean ± SD	0.13	0.00	0.13	0.00	0.13	0.00	0.13	0.00	0.13	0.00	0.13	0.00
WADH
Mean ± SD	0.97	0.20	0.92	0.20	0.94	0.2	0.93	0.20	0.93	0.20	0.97	0.18
Drug	Triptorelin 3.75 – 11.25
Years	2007		2008		2009		2010		2011		2012
Sum of days of treatment
Median	322		360		360		360		360		270
Range	90	360	90	365	56	365	90	360	90	365	56	365
WRDD
Mean ± SD	0.08	0.13	0.07	0.12	0.03	0.13	0.04	0.11	0.08	0.12	0.04	0.11
WPDD
Mean ± SD	0.00	0.13	0.00	0.13	0.00	0.13	0.00	0.13	0.00	0.13	0.00	0.13
WADH
Mean ± SD	0.61	1.00	0.20	0.97	0.79	1.00	0.15	0.94	0.16	0.97	0.15	0.93